Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX02 + pertuzumab + chemotherapy
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of HLX02 (a trastuzumab biosimilar developed by Henlius), pertuzumab, and chemotherapy (such as taxanes, gemcitabine, capecitabine, or vinorelbine). It is being evaluated in a Phase II clinical trial (NCT05188495) led by Peking University Cancer Hospital & Institute for the treatment of HER2-positive metastatic breast cancer in patients who have previously progressed on trastuzumab-based regimens. The regimen utilizes dual HER2 blockade; HLX02 binds to subdomain IV of the HER2 extracellular domain, while pertuzumab binds to subdomain II, preventing HER2 heterodimerization with other HER receptors, particularly HER3. This synergistic approach, combined with the cytotoxic effects of chemotherapy, aims to overcome resistance to single-agent HER2 inhibition and improve progression-free survival in the second-line or later setting.
- Brand names
- ZercepacPerjeta
- Other names
- Henlius trastuzumabtrastuzumab (Henlius)TPC
02
Targets
TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))RNR (Ribonucleotide reductase)HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)
Beyond the preview
Go deeper on HLX02 + pertuzumab + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX02 + pertuzumab + chemotherapy.